Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND1 | P24385 | 2/20 | 0.47 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 12/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2229775 | 0.88 | MKNK1 (0.47) | MKNK1MKNK2CDK2GSK3BKCNH2 | |
| SCHEMBL2227901 | 0.88 | CDK2 (0.57) | CCND1CDK6MKNK1MKNK2CDK2 | |
| SCHEMBL2227980 | 0.87 | CAMKK2 (0.49) | CCND1CDK6MKNK1MKNK2CDK2 | |
| SCHEMBL2227747 | 0.87 | MKNK1 (0.48) | CCND1CDK6MKNK1MKNK2CDK2 | |
| SCHEMBL2230113 | 0.87 | MKNK1 (0.50) | CCND1CDK6MKNK1MKNK2CDK2 | |
| SCHEMBL2231152 | 0.86 | CDK2 (0.47) | CCND1CDK6MKNK1MKNK2CDK2 | |
| SCHEMBL2229894 | 0.85 | CDK2 (0.44) | CCND1CDK6MKNK1MKNK2CDK2 | |
| SCHEMBL2228750 | 0.85 | MKNK1 (0.56) | MKNK1MKNK2CDK2DYRK1A | |
| SCHEMBL2226906 | 0.84 | MKNK1 (0.51) | CCND1CDK6MKNK1MKNK2CDK2 | |
| SCHEMBL2228336 | 0.83 | GSK3B (0.45) | MKNK1MKNK2CDK2GSK3BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183975-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | GOTO YASUHIRO | 2011-07-28 | — | — | US | disclosed |
| US-20110183975-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | GOTO YASUHIRO | 2011-07-28 | — | — | US | disclosed |
| US-20110183975-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | GOTO YASUHIRO | 2011-07-28 | — | — | US | disclosed |
| WO-2010042337-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183975-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | BRIX1, REL, CNKSR1 | CCND1 621/4885CDK6 159/4885MKNK1 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.